Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 7/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | CREBBP | Q92793 | 5/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489500 | 1.00 | PIK3CD (0.39) | PIK3CDPIK3CAPIK3CGJAK2CREBBP | |
| SCHEMBL31489272 | 0.91 | PIK3CD (0.37) | PIK3CDPIK3CAPIK3CGJAK2CREBBP | |
| SCHEMBL31489881 | 0.89 | PIK3CD (0.37) | PIK3CDPIK3CAPIK3CGJAK2 | |
| SCHEMBL31489485 | 0.89 | JAK2 (0.38) | PIK3CDPIK3CAPIK3CGJAK2CREBBP | |
| SCHEMBL31489693 | 0.89 | JAK2 (0.38) | PIK3CDPIK3CAPIK3CGJAK2CREBBP | |
| SCHEMBL31489378 | 0.87 | PIK3CD (0.35) | PIK3CDPIK3CAPIK3CGCREBBPNTRK1 | |
| SCHEMBL31489586 | 0.81 | CREBBP (0.39) | PIK3CDPIK3CAPIK3CGJAK2CREBBP | |
| SCHEMBL31489585 | 0.81 | PIK3CD (0.35) | PIK3CDPIK3CAPIK3CGJAK2 | |
| SCHEMBL31489430 | 0.80 | RIPK1 (0.41) | PIK3CDPIK3CAPIK3CGCREBBPNTRK1 | |
| SCHEMBL31489628 | 0.80 | RIPK1 (0.41) | PIK3CDPIK3CAPIK3CGCREBBPNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |